[go: up one dir, main page]

AU2002221047A1 - Quinazolinone derivatives - Google Patents

Quinazolinone derivatives

Info

Publication number
AU2002221047A1
AU2002221047A1 AU2002221047A AU2104702A AU2002221047A1 AU 2002221047 A1 AU2002221047 A1 AU 2002221047A1 AU 2002221047 A AU2002221047 A AU 2002221047A AU 2104702 A AU2104702 A AU 2104702A AU 2002221047 A1 AU2002221047 A1 AU 2002221047A1
Authority
AU
Australia
Prior art keywords
quinazolinone derivatives
quinazolinone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221047A
Inventor
Kouji Hattori
Junya Ishida
Akinori Iwashita
Kazunori Kamijo
Yoshiyuki Kido
Nobuya Matsuoka
Hiroshi Miyake
Kenji Murano
Isao Nakanishi
Mitsuru Ohkubo
Hirofumi Yamamoto
Shunji Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of AU2002221047A1 publication Critical patent/AU2002221047A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
AU2002221047A 2000-12-11 2001-12-05 Quinazolinone derivatives Abandoned AU2002221047A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR2016A AUPR201600A0 (en) 2000-12-11 2000-12-11 Quinazolinone derivative
AUPR2016 2000-12-11
PCT/JP2001/010601 WO2002048117A1 (en) 2000-12-11 2001-12-05 Quinazolinone derivatives

Publications (1)

Publication Number Publication Date
AU2002221047A1 true AU2002221047A1 (en) 2002-06-24

Family

ID=3826051

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPR2016A Abandoned AUPR201600A0 (en) 2000-12-11 2000-12-11 Quinazolinone derivative
AU2002221047A Abandoned AU2002221047A1 (en) 2000-12-11 2001-12-05 Quinazolinone derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AUPR2016A Abandoned AUPR201600A0 (en) 2000-12-11 2000-12-11 Quinazolinone derivative

Country Status (8)

Country Link
US (1) US20040077667A1 (en)
EP (1) EP1355888A1 (en)
JP (1) JP2004515544A (en)
KR (1) KR20030089691A (en)
CN (1) CN1489581A (en)
AU (2) AUPR201600A0 (en)
CA (1) CA2431406A1 (en)
WO (1) WO2002048117A1 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
WO2002094790A1 (en) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
AUPR975601A0 (en) * 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP2005530785A (en) * 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
NZ537076A (en) * 2002-05-09 2007-06-29 Cytokinetics Inc Pyrimidinone compounds, compositions and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) * 2002-07-23 2008-04-16 Cytokinetics Inc Compounds compositions and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003277079A1 (en) * 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004031171A1 (en) * 2002-10-01 2004-04-15 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
CA2500952C (en) 2002-10-04 2011-04-26 Prana Biotechnology Limited Neurologically-active compounds
EP1558250A4 (en) * 2002-10-30 2006-11-02 Merck & Co Inc GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
CA2507027C (en) 2002-11-22 2012-05-08 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
PL378331A1 (en) * 2003-02-28 2006-03-20 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
HU227948B1 (en) 2003-04-30 2012-07-30 Pecsi Tudomanyegyetem Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
ES2305844T3 (en) 2003-09-16 2008-11-01 Astrazeneca Ab DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASE.
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc Compounds, compositions, and methods
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005054209A1 (en) * 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-­ribose) polymerase inhibitors
EP1687277B1 (en) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
AU2004295059B2 (en) * 2003-12-05 2010-12-16 Janssen Pharmaceutica N.V. 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
WO2005061460A1 (en) * 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
ES2315834T3 (en) 2004-02-03 2009-04-01 Astrazeneca Ab DERIVATIVES OF QUINAZOLINA.
WO2005082368A1 (en) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
CA2557541C (en) * 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
US20050261288A1 (en) * 2004-02-26 2005-11-24 Prakash Jagtap Tetracyclic lactam derivatives and uses thereof
CN1696115B (en) * 2004-05-11 2010-06-09 中国科学院上海药物研究所 Synthetic building block 4-substituent-4-amino-piperidine derivative, its preparation method and use
CN100506802C (en) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 A class of formyl peptide-like receptor-1 modulator, its preparation method and use
CA2571001A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
JP4836946B2 (en) * 2004-06-30 2011-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Substituted 2-alkylquinazolinone derivatives as PARP inhibitors
ES2415771T3 (en) 2004-06-30 2013-07-26 Janssen Pharmaceutica N.V. Quinazoline derivatives as PARP inhibitors
BRPI0512902A (en) * 2004-06-30 2008-04-15 Janssen Pharmaceutica Nv phthalazine derivatives as parp inhibitors
WO2006039545A2 (en) * 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
JP2008531562A (en) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション Tetracyclic amino compounds and tetracyclic carboxamide compounds and methods of use thereof
BRPI0607703A2 (en) * 2005-02-25 2009-09-22 Inotek Pharmaceutical S Corp isoquinoline compounds and methods of use thereof
EP1850848A4 (en) * 2005-02-25 2008-02-20 Inotek Pharmaceuticals Corp TETRACYCLIC SULPHONAMIDE COMPOUNDS AND METHOD OF USE THEREOF
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
WO2006137465A1 (en) * 2005-06-24 2006-12-28 Shionogi & Co., Ltd. Nitrogenated heterocyclic derivative
BRPI0613783A2 (en) * 2005-07-18 2011-02-01 Bipar Sciences Inc cancer treatment
EP1937268A4 (en) * 2005-08-24 2009-07-22 Inotek Pharmaceuticals Corp INDENOISOQUINOLINONE ANALOGUES AND METHODS OF USE
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
WO2007110868A2 (en) * 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007118276A1 (en) 2006-04-14 2007-10-25 Prana Biotechnology Ltd Method of treatment of age-related macular degeneration(amd)
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2059498A4 (en) * 2006-09-05 2011-01-12 Bipar Sciences Inc Treatment of cancer
CN101534836B (en) * 2006-09-05 2011-09-28 彼帕科学公司 Use of PARP inhibitors in the preparation of medicines for treating obesity
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US20100121049A1 (en) * 2007-02-28 2010-05-13 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
WO2008107478A1 (en) * 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
EP2896624B1 (en) * 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
JP5443342B2 (en) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Piperidine / piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
CN101678019B (en) * 2007-06-08 2016-03-30 詹森药业有限公司 Piperidine/piperazine derivatives
ES2483898T3 (en) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Piperidine / Piperazine Derivatives
JP5525447B2 (en) * 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Quinolinone derivatives as PARP inhibitors
JP2011503071A (en) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Treatment of uterine and ovarian cancer with PARP inhibitors alone or in combination with antitumor agents
NZ586125A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
MX2010006154A (en) * 2007-12-07 2010-09-24 Bipar Sciences Inc Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors.
RU2010136966A (en) * 2008-02-04 2012-03-20 Байпар Сайенсиз, Инк. (Us) METHODS FOR DIAGNOSTIC AND TREATMENT OF PARP-MEDIATED DISEASES
BRPI0907916A2 (en) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Spirocycle heterocycles, medicaments containing such compounds, and processes for preparing them
ES2367760T3 (en) * 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. DERIVATIVES OF QUINAZOLINONA AS INHIBITORS OF THE POLYMERIZATION OF THE TUBULIN.
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
WO2009147170A2 (en) 2008-06-05 2009-12-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8859777B2 (en) * 2010-04-30 2014-10-14 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
US8481459B2 (en) * 2010-06-14 2013-07-09 Academia Sinica Chemical inhibitors of ethylene biosynthesis
PL2611300T3 (en) * 2010-09-03 2016-10-31 Substituted annelated dihydropyrimidinone compounds
US8680272B2 (en) 2011-02-15 2014-03-25 Council Of Scientific & Industrial Research 3-arylethynyl substituted quinazolinone compounds
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
MX2014000536A (en) 2011-07-13 2014-12-05 Novartis Ag 4 - piperidinyl compounds for use as tankyrase inhibitors.
EP2731951B1 (en) * 2011-07-13 2015-08-19 Novartis AG 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
CN103781776A (en) * 2011-07-13 2014-05-07 诺华股份有限公司 Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
RU2606635C2 (en) 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Novel compound having parp inhibitory activity
BR112014019357A8 (en) * 2012-02-09 2017-07-11 Merck Patent Gmbh TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANC AND PARP INHIBITORS
AU2013288265B2 (en) 2012-07-09 2017-04-06 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
US9901577B2 (en) * 2013-07-31 2018-02-27 Merck Patent Gmbh Oxoquinazolinyl-butanamide derivatives
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
MA47165B1 (en) 2016-12-30 2021-06-30 Mitobridge Inc Poly-adp-ribose polymerase (parp) inhibitors
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
WO2019088311A1 (en) * 2017-10-31 2019-05-09 주식회사 싸이터스에이치앤비 Compound having stat3 inhibitory activity and use thereof
SMT202300113T1 (en) * 2017-12-21 2023-05-12 Ribon Therapeutics Inc Quinazolinones as parp14 inhibitors
JP7288161B2 (en) * 2017-12-27 2023-06-07 国立研究開発法人理化学研究所 Novel dihydroquinazolinone compound or pharmacologically acceptable salt thereof, and cell growth inhibitor
US12030858B2 (en) 2018-08-27 2024-07-09 Oregon Health & Science University PARP inhibitors for treating cancer and asthma
AR116934A1 (en) * 2018-10-31 2021-06-30 Esteve Pharmaceuticals Sa PIPERAZINIL AND PIPERIDINYL-QUINAZOLIN-4 (3H) -ONE DERIVATIVES WHICH HAVE ACTIVITY AGAINST PAIN
US20220110936A1 (en) * 2019-02-02 2022-04-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
CN109879820B (en) * 2019-02-26 2022-07-19 扬州大学 Synthetic method of quinazolinone heterocyclic compound
CN109820855A (en) * 2019-03-21 2019-05-31 重庆赛拜欧生物医药科技有限公司 Halofuginone hydrobromide is in preparation for treating and preventing the application in ischemic heart medicine
CN110563681B (en) * 2019-09-23 2021-06-04 华东理工大学 Estrogen-related receptor alpha new agonists and their uses
CN112028878A (en) * 2020-09-11 2020-12-04 江阴迈康升华医药科技有限公司 Polyhydroisoquinoline derivative and preparation method and medical application thereof
US11548885B2 (en) 2020-09-21 2023-01-10 Landos Biopharma, Inc. NLRX1 ligands
WO2022072336A1 (en) * 2020-10-01 2022-04-07 University Of Washington Drug-like molecules and methods for the therapeutic targeting of microrna-21
MX2024006074A (en) * 2021-11-19 2024-06-28 Kangbaida Sichuan Biotechnology Co Ltd SELECTIVE PARP1 INHIBITOR AND ITS APPLICATION.
WO2024026424A1 (en) * 2022-07-27 2024-02-01 Black Diamond Therapeutics, Inc. Quinazolinone derivatives as and related uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2027645A1 (en) * 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl quinazolone (4) den vate, process for their preparation and medicinal products containing them
GB9220571D0 (en) * 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity

Also Published As

Publication number Publication date
AUPR201600A0 (en) 2001-01-11
US20040077667A1 (en) 2004-04-22
JP2004515544A (en) 2004-05-27
CA2431406A1 (en) 2002-06-20
KR20030089691A (en) 2003-11-22
WO2002048117A1 (en) 2002-06-20
CN1489581A (en) 2004-04-14
EP1355888A1 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
AU2002221047A1 (en) Quinazolinone derivatives
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AUPR975601A0 (en) Quinazolinone derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2002212436A1 (en) Quinazoline derivatives
AU7860901A (en) Quinazoline derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2002352444A1 (en) Quinazolinedione derivatives
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2001292137A1 (en) Quinazoline derivatives
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002221632A1 (en) 5-amino-1-pentene-3-ol substituted derivatives
AU2002212263A1 (en) Substituted 5-amino-1-pentene-3-ol derivatives
AU2001288484A1 (en) Novel metallotexaphyrin derivatives
AU2001289782A1 (en) Pyrrolotriazolopyrimidinone derivatives
AU2001241084A1 (en) Imidazolylbenzophenone derivatives